Pancreatic Cancer Research

ResearcherUniversity Hospital HeidelbergActive in the last 2 years

Xinchun Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3796-9520; OpenAlex author ID A5100671414. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 12

  1. Comment on "Gut microbiome changes associated with chronic pancreatitis and pancreatic cancer: a systematic review and meta-analysis". First author DOI 10.1097/js9.0000000000003707↗
  2. [Retracted] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2025.13475↗
  3. Aberrant expression of CKS2 induced by ELK1 contributes to malignant progression of pancreatic cancer. Co-author DOI 10.1002/mc.23627↗
  4. [Corrigendum] miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2022.12738↗
  5. Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis. First author DOI 10.3390/cancers14010057↗
  6. PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition. Co-author DOI 10.1159/000489382↗
  7. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. Co-author DOI 10.1186/s12876-018-0891-y↗
  8. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4. First author DOI 10.1186/s13046-018-0807-2↗
  9. miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression. Co-author DOI 10.3892/mmr.2018.8941↗
  10. PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0500-x↗
  11. MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma. Co-author DOI 10.3892/or.2017.6036↗
  12. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.11953↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jishu Wei · 10 shared papers, 2016–2025 · strength 1.08
  2. Yunpeng Peng · 6 shared papers, 2016–2025 · strength 0.71
  3. Yi Miao · 4 shared papers, 2017–2025 · strength 0.66
  4. Yi Miao · 7 shared papers, 2016–2021 · strength 0.60
  5. Ying Xin · 3 shared papers, 2018–2025 · strength 0.49
  6. Yue Fu · 5 shared papers, 2016–2023 · strength 0.47
  7. Changku Jia · 1 shared paper, 2025 · strength 0.42
  8. Jintao Zheng · 1 shared paper, 2025 · strength 0.42
  9. Qiuyang Chen · 4 shared papers, 2017–2023 · strength 0.42
  10. Bin Chen · 2 shared papers, 2022–2025 · strength 0.41
  11. Jingjing Zhang · 1 shared paper, 2025 · strength 0.26
  12. Peng Wang · 2 shared papers, 2017–2023 · strength 0.24
  13. Wentao Gao · 3 shared papers, 2017–2018 · strength 0.22
  14. Kuirong Jiang · 3 shared papers, 2017–2018 · strength 0.22
  15. Lingdi Yin · 3 shared papers, 2016–2018 · strength 0.21
  16. Shangnan Dai · 1 shared paper, 2023 · strength 0.18
  17. Yi Zhu · 2 shared papers, 2017–2018 · strength 0.16
  18. Jingjing Zhang · 1 shared paper, 2022 · strength 0.16
  19. Junli Wu · 2 shared papers, 2017–2018 · strength 0.15
  20. Thomas Moritz Pausch · 1 shared paper, 2021 · strength 0.13
  21. Pascal Probst · 1 shared paper, 2021 · strength 0.13
  22. Thilo Hackert · 1 shared paper, 2021 · strength 0.13
  23. Ulrike Heger · 1 shared paper, 2021 · strength 0.13
  24. Jingjing Zhang · 2 shared papers, 2016–2017 · strength 0.12
  25. Xiaole Zhu · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.